FDA’s interest in fostering innovation in OTC switches may be the most significant factor working in favor of Lipitor as Pfizer Inc. maneuvers toward a possible attempt to bring the statin to nonprescription status.
Research recommendations and regulatory changes in recent years also contribute to an environment likely to be more open to a statin
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?